Xolair reimbursed in China, Concerns over Korea Passing

Announced National Health Insurance Drug List 70 items including Humira, Lynparza

China self-developed immunocancer drug, Davos surpassing Keytruda, Opdivo, listed

Novartis' Xolair is listed as a reimbursed drug in China.

 

Analysts say that 'Korea Passing' is a reality in the industry Xolair, a chronic rash treatment drug, has been cited as one of the leading examples of Korea Passing, 'withholding or withdrawal of reimbursement in Korea to be listed in China and other countries'.

 

China's National Health Insurance Corporation recently released the 'National Basic Medical Insurance Drug List', which is a list of Korea's health insurance benefits.

 

Seventy new drugs are on the reimbusement list Since August, the Chinese government has held a 'medical insurance drug access negotiation', which corresponds to Korea's reimbursement adequacy evaluation and drug price negotiations.

 

Negotiation targets were 119.

 

In the end, 70 new drugs reached an agreement in the drug price negotiation.

 

Xolair withdrew his reimbursement in Korea, finally on the Chinese reimbursement list The most noticeable item is Xolair.

 

Novartis' Xolair passed the Drug Benefits Evaluation Committee in December last year.

 

It was 11 years in Korea.

 

However, Novartis abruptly withdrew from the drug negotiations with the National Health Insurance Corporation.

 

The cause was China.

 

China added Korea as one of its reimbursed reference countries, and Novartis headquarters decided to rule out 'a situation where the reimbursed price could be lowered' in the Chinese market, where purchasing power is 20 times that of Korea.

 

The result was China's listing of reimbursemt.

 

Xolair is listed as one of the 70 reimbusement items listed.

 

However, the listed price of Xolair is not conveyed.

 

The Chinese government has decided to keep the specific reimbursed price secret from this negotiation.

 

Xolair's listing suggests much to Korea in that Korea's passing has become a reality.

 

In Korea, concerns about Korea Passing have been growing over the past two years.

 

An industry official said, "It was finally confirmed that global pharmaceutical companies withdrew from China or gave up their reimbursement in Korea, with the Chinese market in mind." He said, "If Novartis reapply for reimbursement in Korea, the damage is expected not to be small".

 

China has finalized its reimbusement listing policy for 70 new drugs.

 

Chinese Medical Insurance Bureau Website Captured

Reimbursement entry including Humira, Lynparza, Forxiga, Zepatier The newly listed new drugs include 70 items, including 18 Chinese medicines.

 

Anticancer agents, diabetes treatment agents, TNF alpha inhibitors, hepatitis C treatment agents, pulmonary arterial hypertension treatment agents, HIV treatment agents and the like.

 

In case of anticancer drugs, ▲Roche's lung cancer treatment agent 'Alecensa' ▲ AstraZeneca's colorectal cancer treatment 'Tomudex' ▲ AstraZeneca's breast cancer and ovarian cancer treatment 'Lynparza' ▲ 'Jakavi' from Novartis, a treatment for myelofibrosis, a type of rare blood cancer entered the reimbursed list Chinese pharmaceutical companies named their own anticancer drugs.

 

Daboshu ( Sinnatimab), a treatment for Hodgkin's lymphoma jointly developed by Innovent Biologics, in collaboration with Eli Lilly; Hutchison China MediTech's Colorectal Cancer Treatment 'Elunate' (Fruquintinib), The anti-pharmaceutical treatment for breast cancer 'Henrui'(Pyrotinib) is also on the list.

 

Diabetes treatments have also entered the reimbursed list.

 

The GLP-1 series includes AstraZeneca's Byetta and Sanofi's Lyxumia, and among the SGLT-2 lines, AstraZeneca's Forxiga, Boehringer Ingelheim’s Jadiance, Jansen’s Invokana.

 

Etc.

 

were included.

 

Autoimmune disease treatment was also applied as a benefit.

 

Abbvie's Humira, Jansen's 'Remicade', Pfizer's Xeljanes as JAK inhibitor, and , Novartis' 'Xolair' as IgE (immunoglobulin E) inhibitors, respectively are on the list.

 

The hepatitis C treatments included MSD's Zepatier, Gilead's Eplusa and Harvoni.

 

Two new HIV treatments were added, Gilead's Genvoya and Descovy.

 

In addition, GSK's' Trelege Ellipta 'and Novartis' Ultibro' as a COPD therapy inhalation, Novartis' Entresto as a chronic heart failure treatment, Bayer's ‘Eylea 'as a treatment for macular degeneration, and retinal diseases Allegan's Ozurdex was included as a treatment.

 

This is a list of major drugs listed.

 

8 Chinese-developed drugs have been listed on the reimbursement list, including 3 anticancer drugs in the red box.

70 New Drugs Cut Average Price by 61% "Hepatitis C pill, the world's lowest" This reimbursement update is shown in 'Drug cost reduction'.

 

According to major Chinese media, including Xinhua News Agency, the average price cut of 70 new drugs is 61%.

 

Like Korea, China is deeply concerned about the increase in reimbursement and drug costs.

 

Since 2017, China has updated its list every year since 2017, and has been negotiating drug prices with global pharmaceutical companies.

 

The high marketability of the population of more than 1.4 billion is the backdrop for the Chinese government to demand strong drug prices from pharmaceutical companies.

 

In fact, most negotiated drug prices are among the lowest in the world.

 

For example, three hepatitis C treatments reported that the average price was reduced by 85%.

 

Existing hepatitis C treatment prices ranged from ¥ 30,000 to 70,000 (about ₩ 505 to 11.78 million).

 

On the basis of this, it is possible to calculate ¥4500-4500 (about ₩760,000-17.7 million).

 

The Chinese press describes it as "the lowest price in the world." Self developed anticancer drug surpasses Keytruda and Opdivo, listed Another point is the protection of homegrown medicines.

 

Of the 70 drugs added, eight drugs, including Daboshu-Elunate, were developed by Chinese pharmaceutical companies.

 

In particular, Daboshu attracts attention as it is the first to be paid for PD-L1 immunocancer drugs.

 

Other PD-L1 immunocancer drugs, Keytruda and Opdivo, are not yet listed Daboshu is the result of the creation of a major drug, part of China's national science and technology project.

 

After getting a marketing license in December last year, it quickly entered the reimbursement list.

 

This year, the Chinese Society for Clinical Oncology (CSSO) revised its guidelines for lymphoma treatment and encouraged Dabosche's prescription.

 

Elunate is similar.

 

After getting a marketing license in September last year, it entered the reimbursed list relatively quickly.

 

This is a part of the Chinese government's view of in-house developed medicine.